Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Isenberg

Showing results (131-140 of 186) with videos related to

Pageof 19
Sort By:
The Journal of Rheumatology|December 4, 2009
Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) studySahena Haque, Caroline Gordon, David Isenberg, et al.
The Journal of Rheumatology|January 17, 2018
Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus ErythematosusSasha Bernatsky, Rosalind Ramsey-Goldman, Michelle Petri, et al.
Scientific Reports|October 31, 2019
Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus StratificationDaniel Toro-Domínguez, Raúl Lopez-Domínguez, Adrián García Moreno, et al.
Elife|November 21, 2024
ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosisStephanie Guillet, Tomi Lazarov, Natasha Jordan, et al.
Cytokine|May 4, 2021
Differential levels of IFNα subtypes in autoimmunity and viral infectionVincent Bondet, Mathieu P Rodero, Céline Posseme, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 27, 2021
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled TrialDavid Isenberg, Richard Furie, Nicholas S Jones, et al.
Medrxiv : the Preprint Server for Health Sciences|June 17, 2024
ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosisStephanie Guillet, Tomi Lazarov, Natasha Jordan, et al.
Lupus Science & Medicine|September 23, 2025
Towards a minimal core dataset for systemic lupus erythematosus studiesStephen McDonald, Jialin Teng, Chengde Yang, et al.
Annals of the Rheumatic Diseases|May 8, 2012
Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndromeJulia L Newton, James Frith, Danielle Powell, et al.
Annals of the Rheumatic Diseases|June 14, 2013
Health-related utility values of patients with primary Sjögren's syndrome and its predictorsDennis Lendrem, Sheryl Mitchell, Peter McMeekin, et al.
Pageof 19

Showing results (131-140 of 186) with videos related to

Sort By:
Pageof 19
The Journal of Rheumatology|December 4, 2009
Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) studySahena Haque, Caroline Gordon, David Isenberg, et al.
The Journal of Rheumatology|January 17, 2018
Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus ErythematosusSasha Bernatsky, Rosalind Ramsey-Goldman, Michelle Petri, et al.
Scientific Reports|October 31, 2019
Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus StratificationDaniel Toro-Domínguez, Raúl Lopez-Domínguez, Adrián García Moreno, et al.
Elife|November 21, 2024
ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosisStephanie Guillet, Tomi Lazarov, Natasha Jordan, et al.
Cytokine|May 4, 2021
Differential levels of IFNα subtypes in autoimmunity and viral infectionVincent Bondet, Mathieu P Rodero, Céline Posseme, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 27, 2021
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled TrialDavid Isenberg, Richard Furie, Nicholas S Jones, et al.
Medrxiv : the Preprint Server for Health Sciences|June 17, 2024
ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosisStephanie Guillet, Tomi Lazarov, Natasha Jordan, et al.
Lupus Science & Medicine|September 23, 2025
Towards a minimal core dataset for systemic lupus erythematosus studiesStephen McDonald, Jialin Teng, Chengde Yang, et al.
Annals of the Rheumatic Diseases|May 8, 2012
Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndromeJulia L Newton, James Frith, Danielle Powell, et al.
Annals of the Rheumatic Diseases|June 14, 2013
Health-related utility values of patients with primary Sjögren's syndrome and its predictorsDennis Lendrem, Sheryl Mitchell, Peter McMeekin, et al.
Pageof 19